Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are lymphocyte-mediated scarring alopecias which clinically affect primarily the anterior and mid-scalp. However, unaffected scalp areas have not yet been investigated in a systemic manner. In this study, we assessed histopathologic changes in affected and unaffected scalp in both diseases and healthy control subjects and compared these findings with clinical signs and scalp symptoms. We have demonstrated that "normal-appearing" scalp that is devoid of clinical lesions of LPP and FFA showed lymphocytic perifollicular inflammation around the isthmus/infundibulum areas in 65% of biopsy specimens, perifollicular fibrosis in 15% and mucin deposits in 7.5% of the cases. None of these findings were found in control samples. No direct correlation was found between the degree of histopathological inflammation, scalp symptoms and clinical lesions in the corresponding affected scalp areas. This preliminary study suggests that both diseases may be more generalized processes which affect the scalp and therefore need systemic or total scalp therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.13834DOI Listing

Publication Analysis

Top Keywords

scalp areas
12
"normal-appearing" scalp
8
lichen planopilaris
8
frontal fibrosing
8
fibrosing alopecia
8
scalp
8
unaffected scalp
8
scalp symptoms
8
clinical lesions
8
areas
4

Similar Publications

Novel therapeutic approaches on molecular pathways are being developed to treat inflammatory and autoimmune cutaneous dermatoses. Apremilast is an orally administered small-molecule phosphodiesterase 4 (PDE4) inhibitor that upregulates intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels to mediate a large array of proinflammatory cytokines as well as exerts its anti-inflammatory functions and therapeutic efficacy in skin diseases rather than an immunosuppressive mode of action. Early-phase clinical trials have demonstrated its favorable efficacy such that the United States Food and Drug Administration (USFDA) has approved its use for the treatment of psoriasis, psoriatic arthritis, and Behçet's syndrome.

View Article and Find Full Text PDF

Brain metastasis from cutaneous angiosarcoma of the scalp is rare, and the characteristics and optimal treatment remain poorly understood. Herein, we report three cases of brain metastasis originating from cAS of the scalp. Case 1: An 81-year-old male developed lung metastasis 2.

View Article and Find Full Text PDF

Cutaneous angiosarcoma of the scalp is a rare, highly aggressive malignant tumor. A 67-year-old man with initial presentation of intermittent facial puffiness, periorbital swelling, and a gradually increasing painless ulcerative lesion on the right side of his forehead, and biopsy-proven cutaneous angiosarcoma, underwent 18F-FDG-PET/CT for initial staging. FDG-PET/CT demonstrated increased tracer uptake in the scalp and facial regions, encompassing periorbital and perinasal areas.

View Article and Find Full Text PDF

Introduction: While there are many treatment options available for Tourette Syndrome, including pharmacotherapy and behavioral therapy, these treatments may lead to incomplete symptom relief or side effects. Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that uses constant, low current delivered via electrodes attached to the scalp in order to modulate brain signals. tDCS has been explored as an alternative treatment option for tics in both pediatric and adult populations.

View Article and Find Full Text PDF

Learning disabilities (LD) compromise academic achievement in approximately 5-10% of school-aged children, yet the neurophysiological signatures that could facilitate earlier detection or stratification remain poorly defined. Resting-state electroencephalography (rs-EEG) offers millisecond resolution and is cost-effective, but its findings have never been synthesized systematically across pediatric LD cohorts. Following a PROSPERO-registered protocol (CRD420251087821) and adhering to PRISMA 2020 guidelines, we searched PubMed, Embase, Web of Science, Scopus, and PsycINFO through 31 March 2025 for peer-reviewed studies that recorded eyes-open or eyes-closed rs-EEG using ≥ 4 scalp electrodes in children (≤18 years) formally diagnosed with LD, and compared the results with typically developing peers or normative databases.

View Article and Find Full Text PDF